Antisense Oligonucleotides Market
Number of pages: 100 | Report Format: PDF | Published date: 06 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 1,919.2 million |
|
Revenue forecast in 2031 |
US$ 4,618.7 million |
|
Growth Rate |
CAGR of 10.25% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast period |
2023-2031 |
|
Historical Years |
2021 |
|
Segments covered |
Drug, Indications, End User, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global antisense oligonucleotides market was valued at US$ 1,919.2 million in 2022 and is expected to register a revenue CAGR of 10.25% to reach US$ 4,618.7 million by 2031.
Market Fundamentals
Antisense oligonucleotides (ASOs) are agents for regulating inappropriate gene expression in pathological situations by specifically inhibiting the production of their mRNA targets. Antisense oligonucleotide technologies operate on the assumption that blocking mRNA activity might selectively inhibit the production of undesired genes. The technique has appeared to be useful for the research and development of drugs.
Antisense oligonucleotides are classified into two major subtypes RNase H competent and steric block. The endogenous RNase H enzyme RNASEH1 detects and catalyzes the degradation of RNA-DNA heteroduplex substrates generated when DNA-based oligonucleotides bind to their respective mRNA transcripts. In recent years, antisense oligonucleotide technologies have been widely exploited as potent and promising tools for drug development. The number of antisense compounds advancing through clinical studies is also increasing. Moreover, the technologies are projected to become a reality shortly, providing a straightforward and efficient drug discovery and development method.
Furthermore, the technique has been proven to be an effective therapeutic agent and crucial molecular biology reagent. ASOs are employed to develop mRNA selective knockouts in both in vitro and in vivo processes. Antisense oligonucleotides may selectively target genes, especially those that are challenging to target with small molecule inhibitors or neutralizing antibodies; therefore, they can be employed for many treatments.
[9769868]
Market Dynamics
Increasing the application of antisense oligonucleotides in research, genetic testing, and forensics is the major factor in increasing the market revenue growth of antisense oligonucleotides. This is due to their ability to target and modify gene expression. This technology can be used to modulate the expression of specific genes, allowing researchers to understand gene function and regulation better. Antisense oligonucleotides are also used to modulate gene expression in various diseases, such as cancer, infectious diseases, and genetic disorders, providing researchers with a powerful means to identify novel therapeutic targets. Furthermore, antisense oligonucleotides can be used to validate hypotheses and provide a better understanding of the underlying biology of diseases, making them a valuable asset in drug discovery and development.
Increasing advancements in antisense oligonucleotides is another potential factor increasing the antisense oligonucleotides market revenue growth. For instance, researchers predicted that antisense oligonucleotides are a novel and extremely promising class of medicines for customized treatment. During the last decade, important chemical advances and enhancements to the foundation of ASOs have converted them into authorized and marketable pharmaceuticals.
The global antisense oligonucleotides market is also growing as several market players are showing interest to develop therapeutics based on antisense oligonucleotides. For instance, Bio-Path Holdings, Inc. is researching its potential antisense oligonucleotide-based drug, BP10002 (Liposomal Bcl-2); it is a neutral-charge, liposome-incorporated antisense medication intended to prevent programmed cell death by inhibiting the protein production of Bcl-2.
However, antisense oligonucleotides often degrade before accessing the target, reducing the treatment viability, hence impeding the market revenue growth. Moreover, antisense oligonucleotide products are subject to several strict rules and standards enforced by regulatory bodies, which is anticipated to slow market revenue growth.
Market Ecosystem
The global antisense oligonucleotide market has been analyzed from four perspectives: Drug, Indications, End User, and Region.
Antisense Oligonucleotides Market by Drug
[56889]
Based on the drug, the global antisense oligonucleotides market has been segmented into fomivirsen, mipomersen, nusinersen, patisiran, inotersen, eteplirsen and others.
The nusineren segment has a prominent position in the global antisense oligonucleotides market. Nusinersen, used to treat spinal muscular atrophy, is one of the most popular ASO drugs. The drug works by improving the synthesis of a survival motor neuron (SMN) protein, which is required for appropriate motor neuron growth and function. Eteplirsen is another potential antisense oligonucleotide drug that recently gained attraction for its efficacy in treating Duchenne muscular dystrophy. The drug functions by bypassing a particular exon in the gene that makes the dystrophin protein, which is essential for the healthy operation of muscles.
Antisense Oligonucleotides Market by Indication
Based on indications, the global antisense oligonucleotides market has been segmented into ocular disease, diabetes, cancer, spinal muscular atrophy, and other indications.
The spinal muscular atrophy segment dominated the market with the largest revenue share. Studies have demonstrated that antisense oligonucleotides can improve motor function, strength, and endurance in patients with spinal muscular dystrophy by targeting the abnormal gene responsible for the condition.
Additionally, these oligonucleotides are well-tolerated with minimal side effects. They may also decrease muscle damage and delay the progression of spinal muscular dystrophy. This treatment could potentially provide a long-term, effective approach to treating this debilitating condition.
Antisense Oligonucleotides Market by End User
Based on end users, the global antisense oligonucleotides market has been segmented into basic research, target validations, and genomics.
The basic research segment has the majority of the market revenue share. Antisense oligonucleotides are mostly used in basic research as they can be used to investigate gene function and to identify molecular targets for drug discovery. ASOs can also be used to study the effects of gene expression changes due to mutations or other genetic alterations. In addition, antisense oligonucleotides can be used to generate animal disease models and characterize gene regulatory pathways. Due to their specificity and relatively low toxicity, ASOs have become increasingly popular in basic research.
Antisense Oligonucleotides Market by Region
Based on region, the global antisense oligonucleotides market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North American region has dominated the global antisense oligonucleotides market, owing to advanced healthcare infrastructure and increased spending on research. Additionally, the use of antisense oligonucleotides in treating various diseases, such as cancer and neurological disorders, is growing rapidly. The growing prevalence of life-threatening diseases and the increasing need for personalized medicine in the region are potential driving factors increasing the demand for these therapeutics. Furthermore, a growing number of research and development initiatives by pharmaceutical companies, supportive government policies, and raised venture capital investments are providing further impetus to the growth of the global antisense oligonucleotides market.
The European antisense oligonucleotides market is characterized by rising demand for antisense oligonucleotides in the research and development of many new drugs. Moreover, top players are merging and collaborating with potential players to introduce new and innovative antisense oligonucleotides-based products.
Asia Pacific region is anticipated to grow with high revenue CAGR in the forecast period. This is attributed to increasing investments in biotech research, growing demand for personalized medicine, and a favorable regulatory environment. Additionally, personalized medicine is gaining ground in Asia Pacific, as academics and healthcare professionals are gaining sophisticated knowledge about the efficacy of custom-tailored therapies for better patient outcomes. Antisense oligonucleotides are appropriate for this strategy because they may be tailored to particular requirements.
Competitive Landscape
Some of the prominent market players in the global antisense oligonucleotides market include:
Leading players are progressively focused on implementing strategies such as adopting modern technologies, product advancements, mergers and acquisitions, joint ventures, alliances, and partnerships to strengthen their market positions in the antisense oligonucleotide market. Product launches and approvals and promising product pipelines and acquisitions provide new growth avenues for the company. However, loss of market exclusivity for patented products, intense generic competition, and tightening regulations could affect its business operations.
Strategic Development
High adoption of antisense oligonucleotides in personalized medicines, and its high usage in research and development, is supporting the market revenue growth of the global antisense oligonucleotides market.
Some of the prominent market players in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Biogen, Inc., and Alny.
The spinal muscular atrophy segment is anticipated to grow at a rapid pace.
Asia Pacific is expected to mark the highest growth during the forecast period from 2023 to 2031.
Antisense oligonucleotide products are subject to several strict rules and standards enforced regulatory bodies, which are anticipated to slow market revenue growth.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst